article thumbnail

Medicinal Cannabis Use Approved in French Polynesia

Veriheal

The people of French Polynesia can now legally use medicinal cannabis following the local assembly’s approval of a consumption law. A total of 20 opposition members voted against French Polynesia’s medicinal cannabis law. French Polynesia’s Medicinal Cannabis Law May Be Challenged in France .

article thumbnail

GW’s Cannabis-Based Epilepsy Drug Set For European Approval

Cannabis Law Report

Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. EMA’s human medicines committee had cleared the cannabidiol oral solution, Epidiolex, for use to treat seizures. Here are the takeaways ( Source Fitch). Source: [link].

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Brazil authorizes use of medicine derived from marijuana imported from Colombia

Cannabis Law Report

The authorization for the marketing and use of the medicine in Brazil, that can be sold exclusively in pharmacies and with a prescription , is foreseen in a resolution of the National Health Surveillance Agency (Anvisa, regulator) published this Friday in the Official Gazette. Source: [link].

article thumbnail

Use of Cannabis-based medicinal products: NICE guidelines

Cannabis Law Report

Cannabis-based medicinal products. NICE guideline [NG144] Published date: November 2019. Severe treatment-resistant epilepsy. Severe treatment-resistant epilepsy. 1.4 Severe treatment-resistant epilepsy. Tools and resources. Recommendations. Recommendations for research. Rationale and impact. Recommendations.

article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. TSC is typically diagnosed in childhood. (5)

article thumbnail

And Here We Go Again! NASDAQ Article: Forget Cannabis: Psychedelic Medicine Is the Better Investing Opportunity

Cannabis Law Report

The global march toward cannabis legalization has seemingly awoken another long dormant area of scientific interest: psychedelics as medicine. In lockstep with the FDA’s more open-minded approach toward psychedelic medicine, Denver, Oakland, and Santa Cruz all decided to decriminalize magic mushrooms. Hundreds of other U.S.

article thumbnail

Insys Development Company, Inc. v. GW Pharma Limited Co., Case No. IPR2017-00503 – PTAB Only Partially Smokes Cannabis Patent

Cannabis Law Report

January 2019. s patent directed to the use of cannabinoids, including cannabidiol (“CBD”), in the treatment of certain types of epilepsy. As the first post-grant trial on medicinal cannabis, this decision thus removes a few unknowns for those who own or are seeking patents in this space. Insys Development Company, Inc.